Moreover, the 21-gene expression assay (Genomic Health Inc., Redwood City, CA, USA) is routinely used in ER-positive/HER2-negative, lymph node (LN)-negative female breast cancer patients to determine those who will derive the most benefit from systemic chemotherapy prescription [[9], [10], [11]]. Here, ERBB2 is linked to breast carcinoma.